Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP trial
2024-513092-40-00Phase 4Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, open-label trial of clopidogrel, dipyridamole, aspirin and carbasalate calcium in cryptogenic stroke and transient ischaemic attack (TIA) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Primary composite vascular endpoint. Planned start Dec 2024; status: authorised.
02
Drugs
clopidogreldipyridamoleaspirincarbasalate calcium
03
Conditions
cryptogenic stroketransient ischaemic attack (TIA)
Beyond the preview
Go deeper on 2024-513092-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513092-40-00.